RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (RLMD) on September 16, 2025, regarding events occurring on September 15, 2025. The Company is incorporated in Nevada and its common stock trades on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance event regarding the Company's stock listing status.
Material Changes
The primary material event reported is the restoration of compliance with NASDAQ listing requirements. Specifically:
- The Company received written notice from the NASDAQ Listing Qualifications Department on September 15, 2025.
- The notice confirmed that for 10 consecutive trading days (August 29, 2025, to September 12, 2025), the closing bid price of the Company's common stock was at least $1.00 per share.
- This performance satisfied NASDAQ Listing Rule 5550(a)(2).
- NASDAQ has officially closed the matter regarding the Company's compliance status.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the listing compliance issue. The document incorporates a press release dated September 15, 2025, as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the current trading price of RLMD to ensure continued compliance with the $1.00 minimum bid price requirement.
- Confirm the official closure of the listing deficiency with NASDAQ via the attached press release (Exhibit 99.1).
- Note that this filing does not contain updated financial statements or operational results.